Skip to main content
. 2019 Mar 15;1(3):115–118. doi: 10.1016/j.cjco.2019.02.005

Figure 1.

Figure 1

Low-density lipoprotein cholesterol (LDL-C) response to evolocumab according to genotype. LDL-C levels before and after evolocumab treatment in each patient, grouped into (A) monogenic (N = 32; all heterozygotes) and (B) polygenic (N = 7) hypercholesterolemia, where pretreatment levels indicate the most recent lipid panel result before evolocumab initiation, and post-treatment levels indicate results 12 weeks after first injection. Means ± standard deviations (SDs) are shown, as are the numbers of treated individuals who attained target LDL-C <2 mmol/L.